Blood Clotting Risks During Pregnancy and Delivery
July 20, 2015
GRIFOLS-Hereditary A.T. Deficiency
There may be a ticking time bomb in your veins. It’s rare, potentially deadly, hereditary, and worst of all, it’s most dangerous to expecting and new mothers. It’s called Hereditary Antithrombin (AT) Deficiency. It is among the rarest, most dangerous, and most under-diagnosed of all inherited blood clotting disorders. And it’s highly unlikely that your OBGYN will test you for it. The statistics are sobering: patients with Hereditary AT Deficiency have a 20-times higher risk of blood clots, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). One in three pulmonary embolisms may be fatal. Unfortunately if you’re pregnant, the risk increases even further. In fact, up to 70% of women with Hereditary AT Deficiency who do not receive preventative treatment may experience blood clotting before or after childbirth. The greatest risk is in the first week post-partum. One thing you can do is be proactive. Bring up AT Deficiency to your OBGYN and ask to be tested before you give birth. If you do need treatment, Thrombate III® (antithrombin III [human]) is indicated for the prevention and treatment of thromboembolism. Early diagnosis and preventative treatment could improve your chances for a healthy pregnancy and delivery.
Clinical trials are an opportunity for patients to receive promising new therapies, but they can be difficult to navigate. Learn how The Leukemia & Lymphoma Society’s Clinical Trial Support Center is helping guide patients.
There are approximately 7,000 known rare diseases, but only 5% of them have an approved treatment. Learn how early intervention, proper management strategies, and clinical trials are key for rare disease patients.
Friedreich’s Ataxia is a progressive and debilitating neurological disorder. It's important to recognize symptoms and obtain an early diagnosis to properly manage the condition.